Meta-analyses of FibroTest diagnostic value in chronic liver disease
<p>Abstract</p> <p>Background</p> <p>FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients with chronic hepatitis C (CHC).</p> <p>The aim was to test two hypotheses, one, that the FT diagnostic value was similar in the three other f...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2007-10-01
|
| Series: | BMC Gastroenterology |
| Online Access: | http://www.biomedcentral.com/1471-230X/7/40 |
| _version_ | 1811258516175847424 |
|---|---|
| author | Bourliere Marc Zoulim Fabien Lebrec Didier Thabut Dominique Naveau Sylvie Imbert-Bismut Françoise Castera Laurent Ratziu Vlad Halfon Philippe Morra Rachel Poynard Thierry Cacoub Patrice Messous Djamila Munteanu Mona de Ledinghen Victor |
| author_facet | Bourliere Marc Zoulim Fabien Lebrec Didier Thabut Dominique Naveau Sylvie Imbert-Bismut Françoise Castera Laurent Ratziu Vlad Halfon Philippe Morra Rachel Poynard Thierry Cacoub Patrice Messous Djamila Munteanu Mona de Ledinghen Victor |
| author_sort | Bourliere Marc |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients with chronic hepatitis C (CHC).</p> <p>The aim was to test two hypotheses, one, that the FT diagnostic value was similar in the three other frequent fibrotic diseases: chronic hepatitis B (CHB), alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD); and the other, that the FT diagnostic value was similar for intermediate and extreme fibrosis stages.</p> <p>Methods</p> <p>The main end points were the FT area under the ROC curves (AUROCs) for the diagnosis of bridging fibrosis (F2F3F4 vs. F0F1), standardized for the spectrum of fibrosis stages, and the comparison of FT AUROCs between adjacent stages. Two meta-analyses were performed: one combining all the published studies (random model), and one of an integrated data base combining individual data. Sensitivity analysis integrated the independency of authors, lenght of biopsy, prospective design, respect of procedures, comorbidities, and duration between biopsy and serum sampling.</p> <p>Results</p> <p>A total of 30 studies were included which pooled 6,378 subjects with both FT and biopsy (3,501 HCV, 1,457 HBV, 267 NAFLD, 429 ALD, and 724 mixed). Individual data were analyzed in 3,282 patients. The mean standardized AUROC was 0.84 (95% CI, 0.83–0.86), without differences between causes of liver disease: HCV 0.85 (0.82–0.87), HBV 0.80 (0.77–0.84), NAFLD 0.84 (0.76–0.92), ALD 0.86 (0.80–0.92), mixed 0.85 (0.80–0.93). The AUROC for the diagnosis of the intermediate adjacent stages F2 vs. F1 (0.66; 0.63–0.68, n = 2,055) did not differ from that of the extreme stages F3 vs. F4 (0.69; 0.65–0.72, n = 817) or F1 vs. F0 (0.62; 0.59–0.65, n = 1788).</p> <p>Conclusion</p> <p>FibroTest is an effective alternative to biopsy in patients with chronic hepatitis C and B, ALD and NAFLD. The FT diagnostic value is similar for the diagnosis of intermediate and extreme fibrosis stages.</p> |
| first_indexed | 2024-04-12T18:14:53Z |
| format | Article |
| id | doaj.art-5e490e9b6b244b8ba88c4e3f3dd3bdbc |
| institution | Directory Open Access Journal |
| issn | 1471-230X |
| language | English |
| last_indexed | 2024-04-12T18:14:53Z |
| publishDate | 2007-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Gastroenterology |
| spelling | doaj.art-5e490e9b6b244b8ba88c4e3f3dd3bdbc2022-12-22T03:21:40ZengBMCBMC Gastroenterology1471-230X2007-10-01714010.1186/1471-230X-7-40Meta-analyses of FibroTest diagnostic value in chronic liver diseaseBourliere MarcZoulim FabienLebrec DidierThabut DominiqueNaveau SylvieImbert-Bismut FrançoiseCastera LaurentRatziu VladHalfon PhilippeMorra RachelPoynard ThierryCacoub PatriceMessous DjamilaMunteanu Monade Ledinghen Victor<p>Abstract</p> <p>Background</p> <p>FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients with chronic hepatitis C (CHC).</p> <p>The aim was to test two hypotheses, one, that the FT diagnostic value was similar in the three other frequent fibrotic diseases: chronic hepatitis B (CHB), alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD); and the other, that the FT diagnostic value was similar for intermediate and extreme fibrosis stages.</p> <p>Methods</p> <p>The main end points were the FT area under the ROC curves (AUROCs) for the diagnosis of bridging fibrosis (F2F3F4 vs. F0F1), standardized for the spectrum of fibrosis stages, and the comparison of FT AUROCs between adjacent stages. Two meta-analyses were performed: one combining all the published studies (random model), and one of an integrated data base combining individual data. Sensitivity analysis integrated the independency of authors, lenght of biopsy, prospective design, respect of procedures, comorbidities, and duration between biopsy and serum sampling.</p> <p>Results</p> <p>A total of 30 studies were included which pooled 6,378 subjects with both FT and biopsy (3,501 HCV, 1,457 HBV, 267 NAFLD, 429 ALD, and 724 mixed). Individual data were analyzed in 3,282 patients. The mean standardized AUROC was 0.84 (95% CI, 0.83–0.86), without differences between causes of liver disease: HCV 0.85 (0.82–0.87), HBV 0.80 (0.77–0.84), NAFLD 0.84 (0.76–0.92), ALD 0.86 (0.80–0.92), mixed 0.85 (0.80–0.93). The AUROC for the diagnosis of the intermediate adjacent stages F2 vs. F1 (0.66; 0.63–0.68, n = 2,055) did not differ from that of the extreme stages F3 vs. F4 (0.69; 0.65–0.72, n = 817) or F1 vs. F0 (0.62; 0.59–0.65, n = 1788).</p> <p>Conclusion</p> <p>FibroTest is an effective alternative to biopsy in patients with chronic hepatitis C and B, ALD and NAFLD. The FT diagnostic value is similar for the diagnosis of intermediate and extreme fibrosis stages.</p>http://www.biomedcentral.com/1471-230X/7/40 |
| spellingShingle | Bourliere Marc Zoulim Fabien Lebrec Didier Thabut Dominique Naveau Sylvie Imbert-Bismut Françoise Castera Laurent Ratziu Vlad Halfon Philippe Morra Rachel Poynard Thierry Cacoub Patrice Messous Djamila Munteanu Mona de Ledinghen Victor Meta-analyses of FibroTest diagnostic value in chronic liver disease BMC Gastroenterology |
| title | Meta-analyses of FibroTest diagnostic value in chronic liver disease |
| title_full | Meta-analyses of FibroTest diagnostic value in chronic liver disease |
| title_fullStr | Meta-analyses of FibroTest diagnostic value in chronic liver disease |
| title_full_unstemmed | Meta-analyses of FibroTest diagnostic value in chronic liver disease |
| title_short | Meta-analyses of FibroTest diagnostic value in chronic liver disease |
| title_sort | meta analyses of fibrotest diagnostic value in chronic liver disease |
| url | http://www.biomedcentral.com/1471-230X/7/40 |
| work_keys_str_mv | AT bourlieremarc metaanalysesoffibrotestdiagnosticvalueinchronicliverdisease AT zoulimfabien metaanalysesoffibrotestdiagnosticvalueinchronicliverdisease AT lebrecdidier metaanalysesoffibrotestdiagnosticvalueinchronicliverdisease AT thabutdominique metaanalysesoffibrotestdiagnosticvalueinchronicliverdisease AT naveausylvie metaanalysesoffibrotestdiagnosticvalueinchronicliverdisease AT imbertbismutfrancoise metaanalysesoffibrotestdiagnosticvalueinchronicliverdisease AT casteralaurent metaanalysesoffibrotestdiagnosticvalueinchronicliverdisease AT ratziuvlad metaanalysesoffibrotestdiagnosticvalueinchronicliverdisease AT halfonphilippe metaanalysesoffibrotestdiagnosticvalueinchronicliverdisease AT morrarachel metaanalysesoffibrotestdiagnosticvalueinchronicliverdisease AT poynardthierry metaanalysesoffibrotestdiagnosticvalueinchronicliverdisease AT cacoubpatrice metaanalysesoffibrotestdiagnosticvalueinchronicliverdisease AT messousdjamila metaanalysesoffibrotestdiagnosticvalueinchronicliverdisease AT munteanumona metaanalysesoffibrotestdiagnosticvalueinchronicliverdisease AT deledinghenvictor metaanalysesoffibrotestdiagnosticvalueinchronicliverdisease |